Buchumschlag

A comment on the interpretation of ligand binding experiments for agonists

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
1. Verfasser:	James P. Higham
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	British Journal of Pharmacology
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

A mitochondria‐targeting and G‐quadruplex structure‐binding ligand inducing calcium overload and ferroptosis in human cancer cells
von: Bo‐Xin Zheng, et al.
Veröffentlicht: (2025)

Progress on the development of Class A GPCR‐biased ligands
von: Paula Morales, et al.
Veröffentlicht: (2024)

Biased agonists of GPR84 and insights into biological control
von: Vincent B. Luscombe, et al.
Veröffentlicht: (2024)

A subtype‐selective photoswitchable agonist for precise manipulation of GABAA receptors
von: Simon Miguel M. Lopez, et al.
Veröffentlicht: (2025)

GLP‐1 agonist‐associated presentations to unscheduled care: An opportunistic pilot study
von: Oliver Thomas, et al.
Veröffentlicht: (2025)

Bioactive ligands targeting ectopic olfactory receptors: Implications for therapeutic strategies
von: Hui Zhao, et al.
Veröffentlicht: (2025)

Comprehensive transduceromic profiling of NOP receptor ligands at different Gα subunits
von: Davide Malfacini, et al.
Veröffentlicht: (2026)

Vestibular modulation by stimulant derivatives in a pentameric ligand‐gated ion channel
von: Emelia Karlsson, et al.
Veröffentlicht: (2025)

The β 2 ‐adrenoceptor agonist formoterol attenuates hallmarks of adrenal Cushing's syndrome
von: Kristan H. Cleveland, et al.
Veröffentlicht: (2026)

Biodiversity2Drugs—Renaissance of exploring nature‐derived peptides for GPCR ligand discovery
von: Christian W. Gruber, et al.
Veröffentlicht: (2025)

Elucidation of the zinc binding site in KCNQ channels
von: Shuo Zhang, et al.
Veröffentlicht: (2025)

Role for the liver X receptor agonist 22‐ketositosterol in preventing disease progression in an Alzheimer's disease mouse model
von: Nikita Martens, et al.
Veröffentlicht: (2025)

Inhibition of TRPM8 function by prostacyclin receptor agonists requires coupling to Gq/11 proteins
von: Cosmin Trif, et al.
Veröffentlicht: (2024)

Advances in binding kinetics and mechanistic PK/PD modelling
von: Bharath Srinivasan
Veröffentlicht: (2024)

Paraoxonase‐2 agonist vutiglabridin promotes autophagy activation and mitochondrial function to alleviate non‐alcoholic steatohepatitis
von: Gu‐Choul Shin, et al.
Veröffentlicht: (2024)

An agonist of the adenosine A2A receptor, CGS21680, promotes corneal epithelial wound healing via the YAP signalling pathway
von: Qiuqin Sun, et al.
Veröffentlicht: (2024)

Hydroxyl chalcone derivative DK02 as a multi‐target‐directed ligand for Alzheimer's disease: A preclinical study in zebrafish
von: Balasubramanian Haridevamuthu, et al.
Veröffentlicht: (2024)

R2R01: A long‐acting single‐chain peptide agonist of RXFP1 for renal and cardiovascular diseases
von: Bruno Poirier, et al.
Veröffentlicht: (2024)

Rhynchophylline as an agonist of sirtuin 3 ameliorates endothelial dysfunction via antagonizing mitochondrial damage of endothelial progenitor cells
von: Lin Lin, et al.
Veröffentlicht: (2025)

Efficacy in diet‐induced obese mice of the hepatotropic, peripheral cannabinoid 1 receptor inverse agonist TM38837
von: Martin E. Cooper, et al.
Veröffentlicht: (2024)

The opioid partial agonist PPL‐138 reduces alcohol self‐administration in rats susceptible to post‐traumatic stress disorder
von: Andrea Cippitelli, et al.
Veröffentlicht: (2025)

Why classical receptor theory, which ignores allostery, can effectively measure the strength of an allosteric effect as agonist's efficacy
von: H. Ongun Onaran, et al.
Veröffentlicht: (2024)

Matsupexole: A novel nonergot dopamine receptor agonist with sustained efficacy in a rat model of Parkinson's disease and limited off‐target activity
von: Takayuki Suzuki, et al.
Veröffentlicht: (2026)

Feedback control of excitability and high K + induced epileptiform bursts in male rat hippocampal slices with a photocaged adenosine A 1 receptor agonist
von: Erine Craey, et al.
Veröffentlicht: (2026)

Flecainide binding dynamics in voltage‐gated sodium channels: A comparative isoform analysis of the state‐dependent block
von: Tatsuo Munakata, et al.
Veröffentlicht: (2026)

Novel FKBP prolyl isomerase 1A (FKBP12) ligand promotes functional improvement in SOD1G93A amyotrophic lateral sclerosis (ALS) mice
von: Laura Moreno‐Martinez, et al.
Veröffentlicht: (2025)

Systemic EP4 receptor agonist and Arginase‐1 therapy in a murine model of chronic asthma and influenza virus‐induced asthma exacerbation
von: Tim Lange, et al.
Veröffentlicht: (2025)

Pharmacodynamics of the orexin type 1 (OX1) receptor in colon cancer cell models: A two‐sided nature of antagonistic ligands resulting from partial dissociation of Gq
von: Valérie Gratio, et al.
Veröffentlicht: (2024)

Fatty acid binding protein 3 activates endothelial adhesion of circulating monocytes and impairs endothelial angiogenesis
von: Yen‐Wen Wu, et al.
Veröffentlicht: (2025)

The pancreatic signal of GLP‐1 receptor agonists: A biliary phenomenon rather than direct toxicity
von: Andro Koren, et al.
Veröffentlicht: (2026)

ESG‐1‐60 and ESG‐1‐61: Novel dopamine D3 receptor‐preferring partial agonists/antagonists that inhibit cocaine taking and seeking in rodents
von: Omar Soler‐Cedeño, et al.
Veröffentlicht: (2025)

Characterisation of cotadutide's dual GLP‐1/glucagon receptor agonistic effects on glycaemic control using an in vivo human glucose regulation quantitative systems pharmacology model
von: Rolien Bosch, et al.
Veröffentlicht: (2024)

GLP‐1 receptor agonists and reduced dementia risk: Real‐world evidence stacks up
von: Yun Wah Lam, et al.
Veröffentlicht: (2026)

Dimerisation of the VIP receptor VIPR2 is essential to its binding VIP and Gαi proteins, and to its functions in breast cancer cells
von: Satoshi Asano, et al.
Veröffentlicht: (2025)

α‐Linolenic acid suppresses Th17 cell differentiation to mitigate allergic rhinitis by binding to Lyn kinase in mast cells
von: Yuejin Wang, et al.
Veröffentlicht: (2026)

The PARP inhibitor rucaparib blocks SARS‐CoV‐2 virus binding to cells and the immune reaction in models of COVID‐19
von: Henrietta Papp, et al.
Veröffentlicht: (2024)

EXPRESSION OF CONCERN: Rosiglitazone and 15‐deoxy‐Δ 12,14 ‐prostaglandin J 2 , ligands of the peroxisome proliferator‐activated receptor‐γ (PPAR‐γ), reduce ischaemia/reperfusion injury of the gut
Veröffentlicht: (2024)

Changes in the plasma protein‐binding rate of remifentanil during cardiopulmonary bypass
von: Hiroshi Ueda, et al.
Veröffentlicht: (2024)

Efficacy and safety of a selective partial agonist for nociception/orphanin‐FQ peptide (NOP) receptors in patients with insomnia disorder
von: Garth T. Whiteside, et al.
Veröffentlicht: (2025)

Resveratrol, a novel inhibitor of fatty acid binding protein 5, inhibits cervical cancer metastasis by suppressing fatty acid transport into nucleus and downstream pathways
von: Xiao Chen, et al.
Veröffentlicht: (2024)